Identifying specific biomarkers and clinical characteristics is crucial for predicting a patient's response to both existing and emerging treatments for chronic spontaneous urticaria, thereby moving ...

The cohort included 325 white children (56.4%), with 113 on placebo and 212 on omalizumab; 99 Black children (17.2%), with 30 on placebo and 69 on omalizumab; and 152 children who were Asian ...

Omalizumab treatment was able to significantly decrease extra-respiratory symptoms in patients with aspirin-exacerbated respiratory disease (AERD), with or without use of aspirin, a study has found.

During the year before omalizumab treatment, 16 (59.3%) patients experienced episodic AERD-related extra-respiratory chest symptoms including angina-like chest pain; gastrointestinal (GI) symptoms ...

Omalizumab for 16 weeks increased the reaction threshold for peanut and other common food allergens in children as young as age 1 year with multiple food allergies, according to study findings ...

Results from the Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients study (OSMO; ClinicalTrials.gov Identifier: NCT02654145) demonstrated that after directly switching ...

4 Consideration of the evidence The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of omalizumab, having considered evidence on the nature of chronic ...

Treatment with omalizumab, an anti-IgE antibody, significantly increased the amount of peanut and other common food allergens individuals with multi-food allergies could consume without a reaction ...

A Northwestern study found that the asthma drug zileuton prevents food allergy anaphylaxis in mice by blocking allergen absorption in the gut. The research reveals a new mechanism driving allergic ...

March 12, 2003 (Denver) — The anti-IgE monoclonal antibody omalizumab appears to inhibit IgE-mediated nasal symptoms within a week, which suggests that it could be useful in quickly controlling ...

Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review" report has been added to ResearchAndMarkets.com's offering.This product provides ...

The company presented evidence on a narrower population than covered by the marketing authorisation based on feedback from UK clinicians on the appropriate population for omalizumab in England. It ...